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Two signiﬁcant barriers have limited the development of effective treatment of Alzheimer’s disease. First, for many cases the
aetiology is unknown and likely multi-factorial. Among these factors, hypercholesterolemia is a known risk predictor and has
been linked to the formation of b-amyloid plaques, a pathological hallmark this disease. Second, standardized diagnostic tools
are unable to deﬁnitively diagnose this disease prior to death; hence new diagnostic tools are urgently needed. Magnetic
resonance imaging (MRI) using high ﬁeld-strength scanners has shown promise for direct visualization of b-amyloid plaques,
allowing in vivo longitudinal tracking of disease progression in mouse models. Here, we present a new rabbit model for
studying the relationship between cholesterol and Alzheimer’s disease development and new tools for direct visualization of
b-amyloid plaques using clinical ﬁeld-strength MRI. New Zealand white rabbits were fed either a low-level (0.125–0.25% w/w)
cholesterol diet (n=5) or normal chow (n=4) for 27 months. High-resolution (66 66 100mm
3; scan time=96min) ex vivo
MRI of brains was performed using a 3-Tesla (T) MR scanner interfaced with customized gradient and radiofrequency coils.
b-Amyloid-42 immunostaining and Prussian blue iron staining were performed on brain sections and MR and histological
images were manually registered. MRI revealed distinct signal voids throughout the brains of cholesterol-fed rabbits,
whereas minimal voids were seen in control rabbit brains. These voids corresponded directly to small clusters of extracellular
b-amyloid-positive plaques, which were consistently identiﬁed as iron-loaded (the presumed source of MR contrast). Plaques
were typically located in the hippocampus, parahippocampal gyrus, striatum, hypothalamus and thalamus. Quantitative analysis
of the number of histologically positive b-amyloid plaques (P50.0001) and MR-positive signal voids (P50.05) found
in cholesterol-fed and control rabbit brains corroborated our qualitative observations. In conclusion, long-term, low-level cho-
lesterol feeding was sufﬁcient to promote the formation of extracellular b-amyloid plaque formation in rabbits, supporting the
integral role of cholesterol in the aetiology of Alzheimer’s disease. We also present the ﬁrst evidence that MRI is capable
of detecting iron-associated b-amyloid plaques in a rabbit model of Alzheimer’s disease and have advanced the sensitivity of
MRI for plaque detection to a new level, allowing clinical ﬁeld-strength scanners to be employed. We believe extension of these
technologies to an in vivo setting in rabbits is feasible and that our results support future work exploring the role of MRI as a
leading imaging tool for this debilitating and life-threatening disease.
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Introduction
Alzheimer’s disease is a progressive neurodegenerative disorder
that is the dominant cause of dementia in the elderly. It is
characterized by the accumulation of extracellular b-amyloid
rich plaques and intraneuronal neuroﬁbrillary tangles, neuronal
dysfunction and death, and a gradual deterioration in cognition,
function and behaviour (Khachaturian, 1985). In developed coun-
tries, the prevalence of Alzheimer’s disease doubles with each
passing decade of life such that  5–8% of 65 year olds have
this disease, whereas 30% of 85 year olds are affected (Petrella
et al., 2003; Villemagne et al., 2005). As individuals are now
more likely to live to and beyond the age of Alzheimer’s disease
onset, its incidence is expected to triple over the next 50 years
(Carr et al., 1997).
Two main challenges exist in the effective treatment of
Alzheimer’s disease. First, the aetiology of the disease remains
elusive. While genetic abnormalities appear to be responsible for
a small number of familial early-onset cases, the cause of the vast
number of sporadic late-onset cases is unknown (Canevari and
Clark, 2007). Sporadic Alzheimer’s disease is thought to have mul-
tiple causes, however, numerous lines of evidence point to a lead-
ing role of cholesterol metabolism. The e4
+/e4
+ genotype for
apolipoprotein E, the major cholesterol carrier in the central ner-
vous system, is the strongest independent risk factor for late-onset
Alzheimer’s disease (Corder et al., 1993). Hypercholesterolemia
increases the risk of Alzheimer’s disease in later life (Kivipelto
et al., 2001a, b; Pappolla et al., 2003; Whitmer et al., 2005).
Cholesterol regulates the production of Ab and inﬂuences Ab tox-
icity to neurons (Simons et al., 1998; Yip et al., 2001; Curtain
et al., 2003; Ehehalt et al., 2003). Statins (cholesterol-lowering
drugs) may decrease the risk of developing Alzheimer’s disease
(Wolozin et al., 2000; Li et al., 2007) and improve cognition
and behaviour in mild Alzheimer’s disease patients (Sparks et al.,
2005). Finally, there is an association between atherosclerosis, for
which cholesterol is a key risk factor, and late-life dementia
(Sparks et al., 1990; Hofman et al., 1997).
The second challenge is that standardized ante-mortem assess-
ment of the cognitive status of individuals does not always match
the pathological ﬁndings at autopsy (Hulette et al., 1998; Morris
and Price, 2001; Knopman et al., 2003; Jicha et al., 2006). For this
reason, deﬁnitive diagnosis of Alzheimer’s disease has traditionally
required post-mortem pathological assessment of brain tissue,
emphasizing the need for new methods of identifying this disease
prior to death. Of particular, interest is the development of neu-
roimaging techniques that can directly visualize b-amyloid plaques
since these plaques are formed long (potentially decades) before
the clinical manifestation of the disease. This would allow earlier,
deﬁnitive diagnosis to be possible and direct the use of appropri-
ate, effective treatments at the earliest disease stages. Magnetic
resonance imaging (MRI) has shown signiﬁcant progress towards
reaching this goal. Direct MR visualization of b-amyloid plaques
without contrast agents has been accomplished in both ex vivo
brain samples from Alzheimer’s disease patients (Benveniste et al.,
1999) and in vivo in various transgenic mouse models of
Alzheimer’s disease (Jack et al., 2004, 2005; Vanhoutte et al.,
2005; Braakman et al., 2006). This latter development is particu-
larly signiﬁcant as this can allow the tracking of disease through-
out the whole brain in individual animals over time. Importantly,
two pre-requisites for successfully visualizing b-amyloid plaques
are thought to be the presence of magnetic-susceptibility-
perturbing iron within the plaques and the use of high ﬁeld-
strength MR scanners [7 or 9.4 Tesla (T)] capable of generating
the high-resolution, high signal-to-noise ratio (SNR) images
(micro-MRI) (Jack et al., 2004; Wadghiri et al., 2004; Vanhoutte
et al., 2005). While these studies represent major advances for the
study of Alzheimer’s disease in small animals, to date these
technologies have not been applied to larger animal models of
this disease, nor has direct b-amyloid plaque visualization been
possible using clinical-grade MR scanners, which is an important
goal for future clinical translation.
The work presented here is the result of the serendipitous con-
vergence of two previously unrelated lines of research by our
group. First, we have been studying rabbits fed a low-level cho-
lesterol diet for extended periods of time as a model of athero-
sclerosis (Daley et al., 1994a, b; Ronald et al., 2007). Here,
we demonstrate that this diet also promotes the deposition of
iron-rich b-amyloid plaques in the brains of these animals, provid-
ing a unique larger animal model useful for studying the inﬂuence
of cholesterol on the initiation and progression/regression of
Alzheimer’s disease. Second, we have recently shown that clinical
ﬁeld-strength MRI can be used to non-invasively visualize iron-
loaded cells down to the single cell level in mouse brain
(Heyn et al., 2006a). Here we have optimized this technology,
allowing direct visualization of the iron-rich b-amyloid plaques
formed in our rabbit model. While we do not contend that our
MRI methods are immediately translatable to the clinic, we feel
that this is a signiﬁcant technological advancement in the sensitiv-
ity of MRI for direct detection of plaques, which points to MRI’s
potential for aiding in the study, and potentially diagnosis, of this
debilitating and life-threatening disease.
Methods
Animal model
Animals were cared for in accordance with guidelines of the Canadian
Council on Animal Care. Five New Zealand white rabbits (Charles River
Laboratories, Inc. Wilmington, MA) were fed 100g/day of rabbit chow
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additional age-matched rabbits were fed normal chow and served
as controls [normal chow contained 50.001% (w/w) cholesterol].
Three of these control animals were purchased from the breeder at
22 months of age. These rabbits were fed normal rabbit chow by the
breeder during the ﬁrst 22 months and maintained on this diet once
purchased. Serum cholesterol levels were determined for each animal.
Blood was drawn from the central ear artery following Acepromazine
administration (0.10ml/kg intramuscular) to promote arterial dilation
and analgesia. Samples were mixed with ethylene-diamine tetra-acetic
acid to a ﬁnal concentration of 0.15% (w/v) and serum was collected by
centrifugation at 5000 r.p.m. for 15min at 4 C. Total serum cholesterol
wasmeasuredusingacolorimetricenzyme-basedkit(WakoDiagnositics,
Richmond, VA).
Tissue collection
Animals were sacriﬁced with an overdose of ketamine (2ml intrave-
nous bolus) and pressure-perfused via the left ventricle with a mini-
mum of 1.5l of heparinized (1U/ml) Hanks’ balanced salt solution.
Brains were then carefully dissected and cut down the midline.
One hemisphere from each rabbit was immersed in 10% formalin
for 48h at 4 C and switched to phosphate buffered saline at 4 C
until imaging.
MRI protocol
Half brains were immersed in a proton-free perﬂuorocarbon liquid
(Fluorinert FC-72, 3M, St Paul, MN) and scanned using a 3T whole-
body MR system. In order to collect high-resolution and high signal-
to-noise ratio (SNR) images (required to visualize b-amyloid plaques)
using a clinical ﬁeld-strength scanner, we utilized two custom-built
pieces of MR hardware. First, high-resolution imaging was achievable
by using an insertable gradient coil (inner diameter of 17.5cm) capable
of producing a peak gradient strength (500mT/m) and peak slew rate
(3200T/m/s) more than a factor of 10 higher than corresponding
values for the whole-body gradient coil on the 3T system (gradient
strength and slew rate=40mT/m and 150T/m/s, respectively).
Second, to collect high SNR images a solenoidal radiofrequency coil
(2cm inner diameter) that ﬁt closely around each immersed half brain
was used. Furthermore, high SNR, in addition to high sensitivity to iron
in plaques, was also achieved through use of the three-dimensional
fast imaging employing steady state acquisition (3DFIESTA) pulse
sequence. This sequence has previously been explored in our labora-
tory for high-resolution, high-SNR imaging of single iron-loaded cells
both in vitro and in vivo (Foster-Gareau et al., 2003; Heyn et al.,
2005; Heyn et al., 2006a). Sagittal MR images of each brain were
acquired at a resolution of 66 66 100mm
3 using 3DFIESTA
(repetition time=20ms; echo time=10ms; ﬂip angle=20 ;
bandwidth= 18kHz; phase cycling number/recon=10/sum-of-
squares; scan time=96min).
Histology
Following MRI, 40mm sagittal free-ﬂoating sections of each brain were
collected. Sections were treated with 10% formic acid (pH 1.6) for
20min. Immunostaining was performed using a mouse anti-human
b-amyloid 1–16 primary antibody (1:150 dilution; stains Alzheimer’s
senile plaques; Chemicon International, Temecula, CA), a horse anti-
mouse biotinylated secondary antibody (1:300 dilution; Vector
Laboratories, Burlington, ON), processed using an ABC-HRP complex
solution for 30min (Vector Laboratories, Burlington, ON), and visua-
lized with 30-diaminobenzidine (0.5mg/ml; Sigma-Aldrich Canada,
Oakville, ON). Negative control staining (without addition of primary
antibody) was performed on adjacent sections. Sections were air dried
onto slides and images were taken using a Zeiss Axioplan 2ie micro-
scope (Carl Zeiss Canada, Toronto, ON). Subsequently, Prussian blue
iron staining was performed on each b-amyloid-stained section
and reimaged to visualize iron accumulation and its association with
b-amyloid-positive regions. Slides were further scanned using a Epson
Expression 1680 ﬂat-bed scanner (Model G7808; Epson Canada
Limited; Toronto, ON) to generate low-magniﬁcation images of each
brain section. Finally, the position of each b-amyloid- and iron-positive
plaque was marked on the scanned image and this map of histologi-
cally positive plaques was manually registered to its corresponding
sagittal MR slice using anatomical landmarks (see below). Regions
of well-deﬁned signal loss (signal voids) within the MR slice
were identiﬁed and marked with the person blinded to the histology
results.
MR and histological image analysis
Manual counting of b-amyloid plaques and signal voids was performed
in histological and MR datasets, respectively. For histology, the total
number of regions containing iron-loaded, b-amyloid-positive plaques
in seven brain sections (spaced 1mm apart) from each rabbit was
determined. A positive region was deﬁned as having one or more
plaques spaced closely together (within 100mm). Corresponding MR
slices were selected by matching at least three anatomic landmarks
between histological images and MR images. Speciﬁcally, we com-
pared the formation and shape of the following central brain struc-
tures: the caudate nucleus, the thalamus and the hippocampus. Signal
voids were deﬁned as small image objects characterized by a distinct
focal MR hypointensity compared with its surrounding tissue area.
Extreme caution needed to be applied in order to not mistake intra-
parenchymal voids descending from plaques with those caused by
near-surface air remnants or paramagnetic remains of blood within
vessels (minimized due to perfusion). Therefore, we applied the fol-
lowing rules during quantitation: (i) voids were sharply bounded
hypointense objects of round shape; (ii) voids needed to feature an
intra-parenchymal localization; and (iii) to avoid partial volume effects,
voids needed to exhibit at least a distance of one diameter of their
own size from specimen surfaces or ventricles. Two independent raters
(JAR, HHK) counted the number of voids in the selected MR images.
A conjoint quantiﬁcation of voids by both raters was also performed.
Void location was also recorded as to whether it was clearly present in
grey matter or white matter or in parenchymal locations with no clear
distinction between grey and white matter (referred to as mixed), like
brainstem or basal ganglia.
Statistical analysis
For comparisons of MR and histological data between cholesterol-fed
and control groups two-tailed t-tests were performed. For comparisons
of void locations in cholesterol-fed animal brains, a one-way analysis
of variance (ANOVA) followed by a post hoc Tukey’s multiple com-
parison test was performed. Both Pearson correlational and Bland-
Altman analyses were performed to assess inter-rater variability for
void counting. For all tests, the nominal level of signiﬁcance was
P50.05. GraphPad Prism 4.0a (GraphPad Software Inc., San Diego,
CA) was used for statistical analysis.
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High-resolution MRI revealed distinct
signal voids throughout the brains of
rabbits fed a long-term, low-level
cholesterol diet
Our cholesterol diet regimen was originally proposed to promote
the formation of lipid-rich atherosclerotic aortic plaques in New
Zealand white rabbits (Daley et al., 1994a, b; Ronald et al.,
2007). This diet starts with feeding rabbits a 0.25% w/w choles-
terol-diet for a minimum of 7 months during which time the aver-
age serum cholesterol levels rose  1000mg/dl above baseline
(Table 1). Following this induction period, the cholesterol level is
titrated between 0.125% and 0.25% to maintain an average
serum cholesterol level above 400mg/dl whilst preventing liver
failure due to excessive cholesterol accumulation and toxicity.
In contrast, serum cholesterol levels in control animals was signiﬁ-
cantly lower (average control=31.75mg/dl versus average choles-
terol-fed=668.11mg/dl; P50.001at 21–27 months).
Before any histological results were attained, high-resolution
(66 66 100mm
3) ex vivo MRI (or micro-MRI) of perfused,
ﬁxed half brains from both cholesterol-fed and control rabbits
was performed (Fig. 1). Signal voids were apparent in MR
images throughout the brains of cholesterol-fed rabbits
(Fig. 1A). Importantly, minimal signal voids were seen in images
of control rabbit brains (Fig. 1B).
MR signal voids corresponded to
iron-loaded, b-amyloid-positive
extracellular plaques formed as a
result of cholesterol-feeding
b-Amyloid immunostaining revealed the presence of extracellular
b-amyloid-rich plaques throughout the brains of cholesterol-fed
Table 1 Total serum cholesterol levels (mg/dl) of cholesterol-fed and control rabbits over time
Diet Baseline 1–7 months 8–13 months 14–20 months 21–27 months
Cholesterol-fed 64.85 22.33 (n=5) 1061.20 413.98 (n=5) 428.09 247.38 (n=5) 422.20 221.26 (n=5) 668.11 230.12
# (n=5)
Control 26 (n=1
a)3 1 ( n=1
a)1 8 ( n=1
a)1 7 ( n=1
a) 31.75 12.47 (n=4)
Values represent mean   SD.
a Three age-matched control animals were acquired from breeder at 22 months old.
#P50.001 when compared with control animal values at 21–27 months.
Figure 1 High-resolution (66 66 100mm
3)e x vivo MR images of cholesterol-fed (A) and control (B) rabbit brains. Images of two
different animals from each rabbit group are shown in (A) and (B). Each row of images represents an individual animal with a low
magniﬁcation sagittal image on the left followed by two magniﬁed views on the right to better visualize differences between groups.
Distinct signal voids were clearly seen throughout the brains of cholesterol-fed rabbits (A). Minimal voids were detectable in the
parenchyma of the brains from control rabbits (B).
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diameter) were typically found in clusters within various regions
of the brain including the hippocampus, parahippocampal gyrus,
striatum, hypothalamus and thalamus. No positive staining was
found in negative control stained sections (not shown).
Important for MR detectability, subsequent Prussian blue staining
for iron showed that all plaques found were also rich in iron
(Fig. 2B). Similar to previous ﬁndings seen with high-level (2%),
short-term (10 weeks) cholesterol diets (Sparks et al., 1994), the
low-level (0.125–0.25%), long-term (28 months) cholesterol reg-
imen used here also promoted intraneuronal b-amyloid accumula-
tion in various regions of the brain including the temporal and
frontal cortices, caudate putamen, striatum and hippocampus.
Representative examples of hippocampal and temporal cortex pos-
itive staining are shown in Fig. 3.
Registration between histological images of brain sections and MR
images of half brains showed that iron-loaded, b-amyloid-positive
plaques conﬁrmed by histology corresponded to the signal voids
identiﬁed by MRI (Fig. 4), and therefore we conclude that these
plaques cause the MR-visible signal voids. As shown in a represen-
tative comparison in Fig. 4, many of the plaque clusters (white num-
bers) were readily visualized in the corresponding MR image as
distinct signal voids. Of note, several histologically detected plaques
(red numbers) were not seen as a void in the corresponding MR
image, however, we found that these plaques were typically much
smaller and singular in nature compared to MR-visible plaques.
Quantitation of the histological and MR datasets corroborated
our qualitative observations. Signiﬁcantly more plaque-positive
regions were detected in the histological sections of brains from
rabbits fed the cholesterol-supplemented diet than normal chow
(Fig. 4A; P50.0001). Because signal loss in MRI can be caused by
other non-plaque effects (e.g. incomplete perfusion leaving blood
products or air) some ambiguity can arise when manually counting
signal voids. Therefore, two independent raters counted voids
within the same selected set of MR slices. Both raters indepen-
dently counted signiﬁcantly more signal voids in brains from
cholesterol-fed animals than control animals (data not shown).
However, a signiﬁcantly positive weak correlation was found
(R
2=0.3561; P50.0001) between the two raters and Bland-
Altman analysis revealed that there was a slight bias between
the raters for the number of voids counted in slices with many
voids (Supplementary Fig. S1). Due to this, a consensus void count
was performed. This revealed that signiﬁcantly more signal voids
were identiﬁed in MR images of brains from cholesterol-fed
rabbits than control rabbits (Fig. 4B; P=0.0143). Finally, no pref-
erential location for the MR signal voids within brains from
cholesterol-fed animals was found (Fig. 4C).
Discussion
This study reveals that feeding New Zealand white rabbits a low-
level cholesterol diet for extended periods of time is sufﬁcient to
promote the formation of extracellular b-amyloid plaques resem-
bling those found in Alzheimer’s disease patients. As plasma
cholesterol has repeatedly been shown to be a risk factor
of Alzheimer’s disease for at least 20 years (Sparks et al., 1990;
Corder et al., 1993; Hofman et al., 1997; Simons et al., 1998;
Wolozin et al., 2000; Kivipelto et al., 2001a, b; Yip et al.,
2001; Curtain et al., 2003; Ehehalt et al., 2003; Pappolla et al.,
2003; Sparks et al., 2005; Whitmer et al., 2005; Li et al., 2007),
we are convinced that future study of this model will lead to
consolidation and further understanding of the relationship
between cholesterol and b-amyloid plaque deposition. Along
with this exciting discovery, we have found that these plaques
are consistently loaded with iron. As a result of this, many of
these plaques can be directly visualized as signal voids in MR
images. While the concept of visualizing iron-loaded b-amyloid
plaques using MRI has previously been demonstrated in transgenic
mouse models (Jack et al., 2004, 2005; Vanhoutte et al., 2005;
Braakman et al., 2006), we believe our work represents the
ﬁrst successful attempt at visualizing plaques in a larger and
non-transgenic, spontaneous Alzheimer’s disease animal model.
Of importance is that while our imaging was performed on
Figure 2 (A) Four representative examples of extracellular
b-amyloid-rich plaques formed due to cholesterol-feeding.
As seen, b-amyloid plaques were typically found as clusters
(arrows) and primarily located in the hippocampus, parahip-
pocampal gyrus, striatum, hypothalamus, and thalamus
(images do not represent these locations). (B) Subsequent
Prussian blue iron staining on the same section revealed that
all plaques were consistently rich in iron. Scale bar
represents 50mm.
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imaging of plaques is feasible in the future since the scan time
used here (96min) is well within the anaesthesia limits of this
animal model ( 4h). Finally, an important feature of this work
has been the use of a clinical-ﬁeld strength (3T) scanner, repre-
senting a signiﬁcant advancement in the sensitivity of MRI for the
direct detection of b-amyloid plaques. This lends further support
to the role of MRI as a leading modality in the study and diagnosis
of Alzheimer’s disease.
While we found that cholesterol feeding promoted b-amyloid
plaque deposition, it should be noted that this concept is not
entirely novel. Sparks et al. (1994) were the ﬁrst to show that
feeding rabbits a high-cholesterol (2% w/w) diet promoted the
deposition of b-amyloid in rabbits. As highlighted by Sparks and
Schreurs (2003), this is considered a highly valuable Alzheimer’s
disease model since it displays many of the pathological brain
changes seen in Alzheimer’s disease patients. This includes
evidence of intraneuronal (Sparks et al., 1994) and extracellular
b-amyloid immunoreactivity (Sparks et al., 1994; Sparks and
Schreurs, 2003); microgliosis and apoptosis (Streit and Sparks,
1997); and deﬁciency in the ability to learn a difﬁcult task
(Sparks and Schreurs, 2003). Despite the advantages of the cho-
lesterol-fed rabbit model, two signiﬁcant drawbacks of the high-
level cholesterol diets used in the past are noteworthy. First, the
majority of b-amyloid deposition found in the original Sparks study
(Sparks et al., 1994) was intraneuronal with only one rabbit show-
ing signs of extracellular b-amyloid deposition, the pathognomonic
hallmark of Alzheimer’s disease. Second, high-level cholesterol
feeding can only be maintained for short periods of time.
After  8 weeks on a 2% cholesterol diet, rabbits often succumb
to liver and renal failure (Sparks et al., 1994). It has been shown
that cholesterol feeding and supplementation of drinking water
Fig. 3 Increased intraneuronal b-amyloid accumulation was detected in the brains of cholesterol-fed rabbits (A), but not in control
rabbits (B). Top and bottom images represent positive intracellular staining found in the temporal cortex and CA3 region of the
hippocampus, respectively. Insets in (A) are higher magniﬁcation of regions indicated by arrows. Scale bars in low- and high-magni-
ﬁcation images represent 100 and 20mm, respectively.
Figure 4 (A) Histological brain section stained for both
b-amyloid and iron from a 29-month–old rabbit fed
cholesterol-diet for 27 months. The locations of seven
iron-loaded, b-amyloid-rich plaque clusters are indicated.
(B) Corresponding MR image with the identiﬁed locations of
the histologically conﬁrmed plaques superimposed. Four of the
seven plaque clusters were visualized as signal voids in the
MR image (black numbers). The other three plaques (red
numbers) were not seen as voids in the MR image. (C) Higher
magniﬁcation of both the histology and MRI revealed that
visible plaques were typically large, singular plaques (location
1) or clusters of small plaques (locations 2–4), whereas voids
not seen in MRI were singular and notably smaller (location 6).
Asterisks in 1 indicate areas outside of brain. Scale bar
represents 50mm.
MRI of Alzheimer’s amyloid plaques in rabbit model Brain 2009: 132; 1346–1354 | 1351with copper can improve extracellular b-amyloid deposition
(Sparks and Schreurs, 2003), however, this does not lower
animal mortality rates. Our diet regimen addresses both draw-
backs since all animals fed the low-level (0.125–0.25%) choles-
terol diet developed extracellular b-amyloid plaques, and the more
gradual titration of serum cholesterol levels over time prevented
premature death of the animals. This survivable cholesterol-fed
rabbit model should allow the testing of treatment efﬁcacy after
having established a known b-amyloid plaque burden, and also
may more closely reﬂect the natural history of Alzheimer’s disease
in humans since plaque development occurs over years, even
decades.
Currently, ante-mortem Alzheimer’s disease diagnosis is largely
based on clinical examination, performance on standardized cog-
nitive tests, and the use of structural neuroimaging. MRI is useful
for detecting late-stage brain atrophy due to neuronal loss and can
also report on neuroﬁbrillary tangle burden during the progression
of Alzheimer’s disease (Jack et al., 1992; Gosche et al., 2002;
Jack et al., 2002; Schott et al., 2005; Vemuri et al., 2008).
Unfortunately, clinical MRI measures do not correlate well with
b-amyloid plaque burden (Josephs et al., 2008) and a non-invasive
technique quantifying plaque burden is needed. MR visualization
of b-amyloid plaques has been accomplished in human ex vivo
hippocampal samples using a T2
 -weighted pulse sequence and
7.1T scanner (Benveniste et al., 1999). Jack et al. (2004) used a
9.4-T scanner and customized radiofrequency coil speciﬁc for
imaging murine brain. The ability to directly visualize b-amyloid
plaques using MRI is thought to be due to time-related iron accu-
mulation (Jack et al., 2004; Wadghiri et al., 2004; Vanhoutte
et al., 2005). MRI is sensitive to these iron accumulations due
to T2 and T2
  susceptibility effects that they cause, effectively
spoiling the MR signal normally attained from the brain paren-
chyma. Hence, with sufﬁciently sensitive detection methodology,
iron-loaded b-amyloid plaques can appear as signal voids in
MR images. This typically is achieved by collecting high-resolution,
high-SNR images using high ﬁeld-strength scanners and custom-
ized radiofrequency hardware, and proper choice of pulse sequence
and acquisition timing parameters (T2- and T2
 -weighting), giving
high sensitivity to the iron susceptibility effects. Our detection
scheme is unique in that it uses a combination of a clinical ﬁeld-
strength (3T) scanner, customized gradient and radiofrequency
coils for generating high-resolution, high-SNR images and a
pulse sequence (3DFIESTA) with high SNR efﬁciency and excel-
lent sensitivity to susceptibility contrast created by iron deposits.
These technologies were previously optimized for imaging
of single cells loaded with iron oxide nanoparticles for such
applications as tracking metastatic cancer cells (Heyn et al.,
2006a, b). However, as shown here, this technology is also well
Figure 5 (A) Histological analysis of b-amyloid plaque burden revealed that signiﬁcantly more plaques were seen in cholesterol-fed
than control rabbit brain sections (
   P50.0001). (B) Similarly, consensus MR void analysis conﬁrmed signiﬁcantly more voids in
rabbits fed cholesterol-enriched diets compared with controls (
 P50.05). (C) No differences in void location (grey matter, white
matter or mixed—regions with no clear distinction between grey matter and white matter) were seen in MR images from brains
of cholesterol-fed rabbits.
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within diseases such as Alzheimer’s disease and should allow
tracking of b-amyloid plaque burden in individual animals over
time.
One interesting MRI ﬁnding is that signal voids were detected in
white matter with a similar frequency as in grey matter (Fig. 5C;
not signiﬁcantly different). We believe that the majority of these
voids are iron-loaded plaques as revealed by histology and
identiﬁes a difference of our model compared with Alzheimer’s
disease in humans where plaques are more frequently found in
grey matter. However, some voids may indicate an additional, as
yet unidentiﬁed, pathological consequence of cholesterol feeding
in our rabbits, or b-amyloid plaques in white matter regions of our
rabbit brains may be more enriched with iron than those found
in grey matter, thus being more easily detected with our iron-
sensitive MR technique. At present, it is too early to interpret
this ﬁnding with certainty.
The gradient coil supported use of a clinical ﬁeld-strength scan-
ner also opens the possibility of MRI’s potential for detection of
b-amyloid plaques in humans, as previously reported (Jack et al.,
2004). While signiﬁcant technical challenges would have to be
overcome, several areas of research hint that this might not be
impossible. The availability of whole-body 7T clinical scanners has
led to signiﬁcant SNR gains, and customized head/neck gradient
coils are capable of generating high-resolution images (Chronik
et al., 2000). High-ﬁeld head radiofrequency coils with high SNR
efﬁciency are being developed (Avdievich and Hetherington,
2008), and parallel imaging techniques should lead to signiﬁcant
reductions in scan times (Weiger et al., 2002). By minimizing
ﬁeld inhomogeneities, SNR-efﬁcient, iron-sensitive pulse sequences
such as 3DFIESTA may be implemented on these higher ﬁeld-
strength scanners. Successful imaging of b-amyloid plaques
in humans, combined with structural neuroimaging measures of
atrophy and neuroﬁbrillary tangle burden could provide a compre-
hensive evaluation of Alzheimer’s disease pathogenesis using one
imaging modality.
In conclusion, we present a new survivable cholesterol-fed
rabbit model of Alzheimer’s disease based on titration of ingested
cholesterol over long-time periods combined with a unique clinical
ﬁeld-strength MR technique for direct detection of the brain
b-amyloid plaques. Future study of this model should provide
invaluable information about the relationship between plasma
cholesterol metabolism and Alzheimer’s disease initiation and pro-
gression. Technical development of rabbit-speciﬁc MR technology
should allow these effects to be non-invasively and longitudinally
tracked in individual animals. This would signiﬁcantly advance our
ability to study the efﬁcacy of interventions aimed at decreasing
b-amyloid plaque burden in this animal model and the effects of
cholesterol-lowering interventions on Alzheimer’s disease develop-
ment; ultimately with translation of these effects to Alzheimer’s
disease patients.
Supplementary material
Supplementary material is available at Brain online.
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